secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001048477-23-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M
------------------------------------------------------------------------------

- Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).
- Record H1 2023 revenues of $1.19B (+13% YoY); VOXZOGO Q2 sales surged 229% to $113.3M.
- Full-year VOXZOGO revenue guidance raised to $400-440M (was $380-430M); GAAP net income guidance raised to $165-215M.
- US approved ROCTAVIAN on June 29; commercial launch started; European reimbursement negotiations continue.
- Pivotal program for VOXZOGO in hypochondroplasia to begin in Q4 2023; ongoing studies for age expansion and pipeline updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/0001048477-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/bmrn-20230731.htm
  HTML page:      https://secwatch.observer/filing/0001048477-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer